WST West Pharmaceutical Services Inc

  1. Stocks
  2. Healthcare
  3. NYSE: WST

Price (delayed)

$300.09

Market cap

$22.18B

P/E Ratio

70.94

Dividend/share

$0.5

EPS

$4.23

Enterprise value

$21.99B

Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.westpharma.com/

Highlights

WST's EPS is up by 36% year-on-year and by 9% since the previous quarter
The net income has grown by 36% YoY and by 9% from the previous quarter
The stock's price to earnings (P/E) is 53% more than its 5-year quarterly average of 46.3 and 34% more than its last 4 quarters average of 53.1
WST's debt is up by 21% year-on-year

Key stats

What are the main financial stats of WST
Market
Shares outstanding
73.93M
Market cap
$22.18B
Enterprise value
$21.99B
Valuations
Price to earnings (P/E)
70.94
Price to book (P/B)
12.89
Price to sales (P/S)
10.89
EV/EBIT
56.6
EV/EBITDA
44.39
EV/Sales
10.79
Earnings
Revenue
$2.04B
EBIT
$388.5M
EBITDA
$495.4M
Free cash flow
$275.9M
Per share
EPS
$4.23
Free cash flow per share
$3.73
Book value per share
$23.28
Revenue per share
$27.57
TBVPS
$33.06
Balance sheet
Total assets
$2.58B
Total liabilities
$863.9M
Debt
$325.5M
Equity
$1.72B
Working capital
$790.6M
Liquidity
Debt to equity
0.19
Current ratio
2.77
Quick ratio
1.99
Net debt/EBITDA
-0.39
Margins
EBITDA margin
24.3%
Gross margin
34.8%
Net margin
15.3%
Operating margin
17.8%
Efficiency
Return on assets
13%
Return on equity
19.5%
Return on invested capital
22%
Return on capital employed
18.2%
Return on sales
19.1%
Dividend
Dividend yield
0.17%
DPS
$0.5
Payout ratio
11.8%

WST stock price

How has the West Pharmaceutical Services stock price performed over time
Intraday
0.14%
1 week
0.23%
1 month
6.07%
1 year
90.87%
YTD
5.92%
QTD
5.92%

Financial performance

How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.04B
Gross profit
$709.9M
Operating income
$362.9M
Net income
$311.7M
Gross margin
34.8%
Net margin
15.3%
The net income has grown by 36% YoY and by 9% from the previous quarter
WST's operating income is up by 28% YoY and by 10% from the previous quarter
The gross profit has grown by 21% YoY and by 7% from the previous quarter
WST's net margin is up by 20% year-on-year and by 4.1% since the previous quarter

Growth

What is West Pharmaceutical Services's growth rate over time

Valuation

What is West Pharmaceutical Services stock price valuation
P/E
70.94
P/B
12.89
P/S
10.89
EV/EBIT
56.6
EV/EBITDA
44.39
EV/Sales
10.79
The stock's price to earnings (P/E) is 53% more than its 5-year quarterly average of 46.3 and 34% more than its last 4 quarters average of 53.1
WST's EPS is up by 36% year-on-year and by 9% since the previous quarter
The price to book (P/B) is 101% higher than the 5-year quarterly average of 6.4 and 40% higher than the last 4 quarters average of 9.2
WST's equity is up by 16% year-on-year and by 7% since the previous quarter
The P/S is 114% above the 5-year quarterly average of 5.1 and 41% above the last 4 quarters average of 7.7
West Pharmaceutical Services's revenue has increased by 14% YoY and by 4.7% from the previous quarter

Efficiency

How efficient is West Pharmaceutical Services business performance
West Pharmaceutical Services's ROE has increased by 21% YoY and by 4.8% from the previous quarter
The company's return on assets rose by 17% YoY and by 4% QoQ
WST's return on invested capital is up by 16% year-on-year and by 7% since the previous quarter
WST's return on sales is up by 16% year-on-year and by 6% since the previous quarter

Dividends

What is WST's dividend history
DPS
$0.5
Dividend yield
0.17%
Payout ratio
11.8%
Recent dividends

Financial health

How did West Pharmaceutical Services financials performed over time
WST's total assets is 199% greater than its total liabilities
The total liabilities has increased by 26% year-on-year and by 10% since the previous quarter
WST's total assets is up by 19% year-on-year and by 8% since the previous quarter
WST's debt is 81% smaller than its equity
WST's equity is up by 16% year-on-year and by 7% since the previous quarter
The debt to equity has grown by 6% YoY but it has contracted by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.